

Medications for Treatment of Interstitial Cystitis

REX DANCEL, MD, and ANNE MUNSEY, MD, *University of North Carolina School of Medicine, Chapel Hill, North Carolina*
LARA HANDLER, MLS, *University of North Carolina Health Sciences Library, Chapel Hill, North Carolina*

Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (<http://www.cebm.net/?o=1025>).

The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to <http://www.fpin.org> or email: questions@fpin.org.

This series is coordinated by John E. Delzell, Jr., MD, MSPH, Assistant Medical Editor.

A collection of FPIN's Clinical Inquiries published in *AFP* is available at <http://www.aafp.org/afp/fpin>.

Clinical Question

Which oral medications are effective for the management of interstitial cystitis?

Evidence-Based Answer

There are no long-term clinically effective oral medications. Pentosan (Elmiron) can improve overall symptom scores for interstitial cystitis over three to six months, but it does not improve scores for any of three individual symptoms (dysuria, urgency, frequency) compared with placebo. (Strength of Recommendation [SOR]: B, based on randomized controlled trials [RCTs].) Cimetidine (Tagamet) can improve overall symptom scores for interstitial cystitis, and it improves nocturia and suprapubic pain by about 50%. It does not improve dysuria, urgency, frequency, relief after voiding, or incomplete emptying. (SOR: B, based on a single small RCT.) Amitriptyline and hydroxyzine (Vistaril) should not be used to reduce symptom scores for interstitial cystitis. (SOR: C, based on two small RCTs with conflicting results.)

Evidence Summary

A systematic review of five RCTs included 569 patients in Europe (75% to 97% female; mean age = 43 to 57 years) with interstitial cystitis/painful bladder syndrome.¹ Patients were randomized to pentosan (100 mg three times per day to 200 mg two times per day) or placebo. Patient self-report questionnaires were used to evaluate symptoms. Pentosan produced minimal or no significant improvement in symptom scores, but a pooled analysis of all five trials showed improvement in overall symptom scores for dysuria, nocturia, frequency, and urgency (relative risk = 1.78; 95% confidence interval, 1.34 to 2.35). Three of the studies reported patient-assessed overall improvement rates,

with numbers needed to treat of six to nine. The only adverse effect reported was edema.

A single RCT (n = 36; 97% female; mean age = 42 years) found that cimetidine (400 mg two times per day) improved overall urinary symptom scores (aggregate of nocturia, frequency, urgency, dysuria, relief after voiding, and incomplete emptying) more than placebo (40% vs. 4%, respectively).² Cimetidine improved scores for only two individual symptoms: nocturia (61% vs. 0%; *P* = .006) and suprapubic pain (56% vs. 6%; *P* = .009).

Two RCTs comparing amitriptyline with placebo in patients with interstitial cystitis had conflicting outcomes. A multicenter, multinational RCT involving 271 patients (83% female; mean age = 38 years) found that amitriptyline (10 to 75 mg per day) was no more effective than placebo in reducing symptom scores (*P* = .12).³ An RCT with 50 patients (88% female; mean age = 55 years) demonstrated that amitriptyline (25 to 100 mg per night) decreased mean urinary symptom scores more than placebo (36% vs. 12%; *P* = .005).⁴ Amitriptyline reduced pain and urgency symptoms. Both studies found higher rates of anticholinergic effects with amitriptyline.

An RCT involving 62 U.S. patients (87% female; mean age = 44 years) found that the addition of hydroxyzine (10 to 50 mg per day) to pentosan did not improve symptom scores compared with pentosan plus placebo.⁵ Investigators evaluated aggregate symptom scores for dysuria, urgency, and frequency (symptom score improvement: hydroxyzine 31% vs. placebo 20%; *P* = .26).

Recommendations from Others

Guidelines from the American Urological Association recommend patient education, ►

self-care practices, behavioral modification, and stress management as first-line therapy for patients with interstitial cystitis.⁶ They recommend oral hydroxyzine, cimetidine, amitriptyline, and pentosan as second-line therapies and note that all of these agents may cause adverse effects and have unpredictable effectiveness.

Copyright Family Physicians Inquiries Network. Used with permission.

Address correspondence to Rex Dancel, MD, at rexdance@hotmail.com. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.

REFERENCES

1. Dimitrakov J, Kroenke K, Steers WD, et al. Pharmacologic management of painful bladder syndrome/interstitial cystitis: a systematic review [published correction

appears in *Arch Intern Med.* 2007;167(22):2452]. *Arch Intern Med.* 2007;167(18):1922-1929.

2. Thilagarajah R, Witherow RO, Walker MM. Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. *BJU Int.* 2001;87(3):207-212.
3. Foster HE Jr, Hanno PM, Nickel JC, et al.; Interstitial Cystitis Collaborative Research Network. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. *J Urol.* 2010;183(5):1853-1858.
4. van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. *J Urol.* 2004;172(2):533-536.
5. Sant GR, Propert KJ, Hanno PM, et al.; Interstitial Cystitis Clinical Trials Group. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. *J Urol.* 2003;170(3):810-815.
6. Hanno PM, Burks DA, Clemens JQ, et al.; Interstitial Cystitis Guidelines Panel of the American Urological Association Education and Research, Inc. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. *J Urol.* 2011;185(6):2162-2170. ■

AAFP's "Five Key Metrics for Financial Success"

Master your business. Get back to your patients.

The AAFP's free online educational series, **"Five Key Metrics for Financial Success in Your Practice,"** is designed to provide targeted financial training to practicing family physicians operating as small business owners.

These five- to seven- minute, easily digestible modules will help you understand how to:

- Evaluate your practice's revenue cycle
- Better forecast income and expenses, and
- Address issues preventing timely reimbursement.

Let the AAFP help you master the business side of your practice, so you can get back to your real job: Providing quality care to your patients.